JNJ · Johnson & Johnson
AI read · Good for JNJ
The AI's read
The stronger sales pace and higher company forecast point to more sales this year. Growth in cancer and immune-system medicines, plus $17 billion in cash and securities, supports that reading. MedTech grew more slowly and faced challenges in international markets and Abiomed. Those problems are outweighed by growth across the medicine business and the higher sales forecast.